Portfolio

Morphotek

Founded in 2000, Morphotek developed therapeutic monoclonal antibodies for the treatment on cancer, rheumatoid arthritis and infection disease through the company’s proprietary human antibody technology. In 2007, Eisai Corporation of North America, a subsidiary of Tokyo-based Eisai Co., Ltd., acquired Morphotek for $325M.

Back

Company Profile

Morphotek Logo
  • Founded: 2001